Abstract:Arrhythmia and cardiac hypertrophy are two very common cardiovascular diseases that can lead to heart failure and even sudden death, thus presenting a serious threat to human life and health. According to global statistics, nearly one million people per year die from arrhythmia, cardiac hypertrophy and other associated cardiovascular diseases. Hence, there is an urgent need to find new treatment targets and to develop new intervention measures. Recently, mitochondrial dysfunction has been examined in relation to heart disease with a view to lowering the incidence of arrhythmia and cardiac hypertrophy. The heart is the body's largest energy consuming organ, turning over about 20 kg of adenosine triphosphate (ATP) per day in the mitochondria. Mitochondrial oxidative phosphorylation (OXPHOS) produces up to 90% of the ATP needed by cardiac muscle cells for contraction and relaxation. Dysfunction of heart mitochondria can therefore induce arrhythmia, cardiac hypertrophy and other cardiovascular diseases. Mitochondrial DNA (mtDNA) mutations cause disorders in OXPHOS and defects in the synthesis of muscle contraction proteins. These lead to insufficient production of secondary ATP, increased metabolic requirements for ATP by the myocardium, and the accumulation of reactive oxygen species (ROS). The resulting damage to myocardial cells eventually induces arrhythmia and cardiac hypertrophy. Mitochondrial damage decreases the efficiency of energy production, which further increases the production of ROS. The accumulation of ROS causes mitochondrial damage and eventually leads to a vicious cycle of mitochondrial damage and low efficiency of mitochondrial energy production. In this review, the mechanism underlying the development of arrhythmia and cardiac hypertrophy is described in relation to mitochondrial energy supply, oxidative stress, mtDNA mutation and Mitochondrial dynamics. Targeted therapy for arrhythmia and cardiac hypertrophy induced by mitochondrial dysfunction is also discussed in terms of its potential clinical value. These strategies should improve our understanding of mitochondrial biology and the pathogenesis of arrhythmia and cardiac hypertrophy. They may also identify novel strategies for targeting mitochondria in the treatment of these diseases.

Mitochondrial function in cardiac hypertrophy.

Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy

Mitochondrial Dysfunction in Arrhythmia and Cardiac Hypertrophy

Mitochondrial Dysfunction: A Roadmap for Understanding and Tackling Cardiovascular Aging.

Mitochondrial Dysfunction in Heart Failure and Its Therapeutic Implications

Abstract 15465: Upregulation of Mitochondrial Atpase Inhibitory Factor 1 Mediates Increased Glycolysis in Pathological Cardiac Hypertrophy

Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges

Mitochondrial Dysfunction in Cardiac Disease: The Fort Fell

The role of mitochondria in cardiac development and protection

Mitochondrial ATPase and High-Energy Phosphates in Failing Hearts.

Mitochondria and NLRP3 inflammasome in cardiac hypertrophy

Mitochondrial Function and Dysfunction in Dilated Cardiomyopathy

Mitochondrial Ca2+ Homeostasis: Emerging Roles and Clinical Significance in Cardiac Remodeling

Regulatory Mechanisms of Mitochondrial Function and Cardiac Aging

Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond

Progress of Mitochondrial Function Regulation in Cardiac Regeneration

A Mitochondrial Basis for Heart Failure Progression

Mechanisms of physiological and pathological cardiac hypertrophy

Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease

Mitochondrial Ca2+ Uniporter-Dependent Energetic Dysfunction Drives Hypertrophy in Heart Failure

Mitochondrial Dynamics and Mitophagy in Cardiometabolic Disease